Sign up to save your podcasts
Or
Share JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.
More shows like JAMA Network
View all
JAMA Editors' Summary
135 Listeners
Neurology® Podcast
290 Listeners
JAMA Author Interviews
164 Listeners
Diabetes Core Update
107 Listeners
JAMA Clinical Reviews
495 Listeners
EM Clerkship
809 Listeners
Mayo Clinic Talks
279 Listeners
The Curbsiders Internal Medicine Podcast
3,321 Listeners
JAMA Dermatology Author Interviews
17 Listeners
JAMA Neurology Author Interviews
13 Listeners
JAMA Psychiatry Author Interviews
23 Listeners
JAMA Surgery Author Interviews
6 Listeners
JAMA Medical News
90 Listeners
Core IM | Internal Medicine Podcast
1,108 Listeners
JAMAevidence The Rational Clinical Examination
29 Listeners
Annals On Call Podcast
195 Listeners
Psychopharmacology and Psychiatry Updates
289 Listeners
The Clinical Problem Solvers
517 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
18 Listeners
The Curious Clinicians
366 Listeners
AMA Update
96 Listeners